COMMUNIQUÉS West-GlobeNewswire

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
09/06/2026
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% BURLINGTON, Mass. and JERUSALEM, June 09, 2026 (GLOBE [...]
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
09/06/2026
First Midwest-based account reflects continued execution of the Company's Full Market Release strategy and expansion into additional U.S. territories HINGHAM, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Microbot Medical [...]
CVRx Announces Chief Financial Officer Transition
09/06/2026
MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
BPGbio Appoints Renowned Neuroscientist Eric J. Nestler, M.D., Ph.D., as Chair of Scientific Advisory Board
09/06/2026
World-renowned neuroscientist, Dean of the Icahn School of Medicine at Mount Sinai, and longtime BPGbio’s SAB member, appointed Chair of the SAB, succeeding Chas Bountra, Ph.D., who recently transitioned to Chief [...]
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
09/06/2026
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I as primary [...]
Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T Cell Therapy for Autoimmune Diseases
09/06/2026
Approval paves the way for CTA313 clinical study in the United States for patients with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis BOSTON, June 09, 2026 (GLOBE NEWSWIRE [...]
Vaxart to Participate in BTIG Infectious Disease Day 2026
09/06/2026
SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
The MUHC Foundation’s Le Bal Rouge Gala raises $2,223,306 million to accelerate discovery in health care at the MUHC’s Glen site
09/06/2026
MONTREAL, June 09, 2026 (GLOBE NEWSWIRE) -- The MUHC Foundation’s signature gala, Le Bal Rouge , brought together Montreal’s most passionate leaders in business, philanthropy and health care to celebrate innovation at [...]
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
09/06/2026
Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of [...]
DBV Technologies révise sa participation à la 47ème conférence annuelle Global Healthcare organisée par Goldman Sachs
09/06/2026
Châtillon, France, le 9 juin 2026 DBV Technologies révise sa participation à la 47 ème conférence annuelle Global Healthcare organisée par Goldman Sachs DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq [...]
International Myeloma Foundation (IMF) and International Myeloma Working Group (IMWG) to Honor 2026 Kyle and Durie Achievement Awardees, Dr. Hermann Einsele and Dr. Noopur Raje
09/06/2026
Awarding ceremonies to be held today, June 9, 2026, at the 17th Annual IMWG Summit in Stockholm, Sweden STOCKHOLM, June 09, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the International [...]
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
09/06/2026
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the [...]
Kraig Biocraft Laboratories Sets New All-Time Production Record, Delivering Nearly 2.5 Metric Tons of Recombinant Spider Silk in Single Production Cycle
09/06/2026
Company Continues Delivering on Aggressive 2026 Expansion Strategy as Production Scale Reaches New Heights ANN ARBOR, Mich., June 09, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the [...]
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
09/06/2026
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal [...]
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
09/06/2026
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors Copenhagen, Denmark, 09 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment [...]
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
09/06/2026
Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI [...]
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth
09/06/2026
Alison Strutt appointed as Chief Financial Officer, László Tank ó appointed as Consultant Chief Medical Officer, and Sam Fazeli appointed Non-Executive Director Appointments support MitoRx’s next phase of growth as the [...]
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
09/06/2026
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham - Elraglusib will be assessed in [...]
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
09/06/2026
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial [...]

Pages